Azathioprine

• A single center study to evaluate the safety and tolerability of oral Azathioprine in patients with ADPKD Not authorised
  2025-524313-86-00 Phase II 1 country UZ Leuven
• Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled tr… Pending
  2024-514633-38-00 Phase III 1 country Centre Hospitalier Universitaire Amiens Picardie
• A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active convent… Pending
  2024-516723-14-00 Phase IV 4 countries Karolinska Institutet
• Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAemia after kidney… Pending
  2024-517219-56-00 Phase IV 1 country Paediatrisches Forschungsnetzwerk gGmbH; PROFIL Institut fuer Stoffwechselforsch…
• C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting
  2022-502739-20-00 Phase III 10 countries Pfizer Inc.
• Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock … Recruiting
  2024-518493-14-00 Phase II/III 1 country Les Hopitaux Universitaires De Strasbourg
• Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed moderate-to-severe … Recruiting
  2025-522585-72-00 Phase IV 1 country Universitaetsklinikum Schleswig-Holstein AöR
• Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in participants With ANCA-associated Vasculitis Recruiting
  2023-503184-42-00 Phase IV 7 countries Amgen Inc.
• Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associa… Recruiting
  2024-516243-81-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting
  2024-514648-10-00 Phase III 6 countries Pfizer Inc.
• Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia gravis: a PROBE-type multicenter, open-label, … Recruiting
  2023-506656-24-00 Phase III 1 country Hopital Fondation Adolphe De Rothschild
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k… Recruiting
  2023-510150-17-00 Phase II 13 countries Novartis Pharma AG
• Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing … Recruiting
  2024-516242-19-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Generalized Myasthenia Gravis Recruiting
  2023-509892-17-00 Phase II/III 1 country Kyverna Therapeutics Inc.
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting
  2022-502851-79-00 Phase III 19 countries Argenx
• Infliximab for non-Crohn Anal Fistulas Recruiting
  2022-502263-38-00 Phase II 1 country Aarhus University Hospital
• A RANDOMIZED DOUBLE BLIND, PLACEBO-CONTROLLED NATIONAL MULTICENTER PHASE 3 TRIAL TO EVALUATE THE EFFICACY OF AZATHIOPRINE FOR THE PREVENTION… Recruiting
  2022-500520-30-00 Phase III 1 country Hospices Civils De Lyon
• Study to evaluate the efficacy of immunosuppression (drugs that suppres natural immunologic response of the human body) in treatment of pati… Recruiting
  2024-517484-23-00 Phase IV 1 country Medical University Of Warsaw
• Cyclophosphamide and Azathioprine vs Tacrolimus in antisynthetase syndrome-related interstitial lung disease: multicentric randomized phase … Recruiting
  2024-511868-83-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Evaluation of TNF-alpha antagonists (infliximab) withdrawal in sarcoidosis Ended
  2024-516965-35-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended
  2024-516628-32-00 Phase III 1 country Centre Hospitalier Universitaire De Rennes
• Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended
  2024-512470-10-00 Phase III/IV 1 country Centre Hospitalier Departemental Vendee
• Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted
  2024-516687-28-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended
  2023-506655-19-00 Phase II 7 countries Genentech Inc.

Showing 1–24 of 26 trials